A Phase 3 interventional study of Placebo and Serostim® 4 mg in HIV Infections and Lipodystrophy, sponsored by EMD Serono. Completed at 31 sites in 2 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-07-20.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,803 studies in HIV Infections with a site in United States — 84 open to participants now, 141 under way, 11 of them phase 3. HIV Infections · United States.
Among the 2,803 studies in HIV Infections with a site in United States, this one is the 380th largest by enrollment of the 2,151 interventional ones that give a count, is one of 107 that started in 2004, is one of 305 in phase 3, and was the 1,329th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →84 of the 2,803 studies in HIV Infections with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
Louisiana State University Health Sciences Center in New Orleans · Sites in United States
Ages 40+
American University · Sites in United States
Ages 18+ · Men only
Gilead Sciences · Sites in United States, Australia, Germany and 5 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,803 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 749 · Phase 2 589 · Phase 3 337 · Phase 4 157
First in 1984; this study’s year is marked. 107 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 326 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 60 across the 2,151 interventional studies, 135 across the 350 observational. Of the 2,530 that completed or were terminated, 559 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
858 of 2,803 have an industry lead sponsor. The 10 most frequent:
This study is registered under EMD Serono, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 2 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
51 of the studies in HIV Infections with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06550804Phase 3University of Illinois at ChicagoTesting a Real-time Electronic Antiretroviral Adherence Monitoring Intervention | 2027-03 |
| NCT04833829Emory UniversityCross-disciplinary HIV Integrated Mental Health Support Intervention | 2026-11 |
| NCT04577313University of ConnecticutHIV Treatment Adherence Dose Determination Trial | 2026-11-30 |
| NCT06679751Boston Medical CenterInfectious Disease (ID) Testing OUtreach in Carceral Hubs | 2026-12 |
| NCT06868641Columbia UniversityThe TAIL-PrEP Study | 2026-12 |
Add all 51 to your calendar (.ics) → With an account.
Among the 2,803 studies in HIV Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to determine if Serostim® 4 mg administered daily for 12 weeks as treatment for the abnormal fat accumulation and distribution associated with HIV-associated Adipose Redistribution Syndrome (HARS) reduces Visceral Adipose Tissue (VAT, measured by CT scan) more effectively than placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have written laboratory documentation of an infection by one of the following methods:
Written laboratory documentation of an HIV infection must be obtained prior to randomization. In the absence of documented historical confirmation, an assay of HIV antibodies will be included in the Screening Laboratory Panel. Results will be confirmed with a Western Blot.
Have evidence of excess abdominal adipose deposition when measured by the anthropometric methodology, using the following cut off values:
Have parameter values less than the following limits (using results from the central laboratory):
Female subjects must:
Be post menopausal (>= 1 year) or surgically sterilized (i.e., have undergone tubal ligation or hysterectomy)
or
Use a method for the duration of the study such as:
And
Exclusion Criteria:
Are unable to comply with the Concomitant Therapy restrictions including:
Have ever been diagnosed with any of the following conditions:
In order to participate in this trial a subject must meet all of the inclusion and exclusion criteria specified above. Requests for protocol exceptions/exemptions must come from a participating, fully initiated site at which a prospective patient has consented to undergo screening. Exceptions/exemptions are only allowed by the Trial Director. There is no program in place to allow drug for a single patient IND, or for an expanded access protocol. This statement holds true for both children and adults.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive placebo matched to serostim® as subcutaneous injection daily for a period of 12 weeks.
Drug: Placebo
Subjects will receive Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight for a period of 12 weeks.
Drug: Serostim® 4 mg
All subjects who will be initially randomized to Serostim® 4 mg arm in Period I and will receive placebo matched to Serostim® on alternate days for 24 weeks in Period II.
Drug: Placebo
All subjects who will be initially randomized to Serostim® 4 mg arm in Period I and will receive Serostim® 2 mg on alternate days for 24 weeks in Period II.
Drug: Serostim® 2 mg
All subjects who will be initially randomized to Placebo arm in Period I continue receiving placebo matched to Serostim® on alternate days for 12 weeks followed by Serostim® 4 mg daily 12 weeks.
Drug: Placebo · Drug: Serostim® 4 mg
Placebo matched to serostim® as subcutaneous injection.
Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight.
Also known as: recombinant human growth hormone (r-hGH)
Serostim® 2 mg as subcutaneous injection on alternate days.
Also known as: recombinant human growth hormone (r-hGH)
Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12
Absolute area of VAT was measured by cross-sectional computed tomography (CT) scan at the level of the L4-5 inter-vertebral disk. CT scanning was to be used to assess the cross sectional area of abdominal fat and its distribution between the visceral and subcutaneous compartments, as measured at L4-L5.
Time frame: Baseline, Week 12
Treatment Period I: Change From Baseline in Trunk Fat at Week 12
Changes in trunk fat was measured as changes in mass (kg) on Dual-Energy X-Ray Absorptiometry (DXA) Scan.
Time frame: Baseline, Week 12
Change From Baseline in Patient Reported Outcome of Body Image Distress at Week 12
Body image distress was assessed on a scale ranging from 0 to 100, where 0 = Extremely Upsetting and 100 = Extremely Encouraging.
Time frame: Baseline, Week 12
Treatment Period I: Change From Baseline in Non- High-density Lipoprotein (Non-HDL) Cholesterol at Week 12
Lipid profile data was analyzed for Non-HDL Cholesterol.
Time frame: Baseline, Week 12
Treatment Period II: Failure Rate at Week 36 Based on Visceral Adipose Tissue (VAT) For Subjects Who Received Serostim® 4 mg in Period I
Failure rate based on VAT was assessed by CT scan at L4-L5. The failure rate was defined as the percentage of subjects who regained \>50% of their VAT lost in Treatment Period I. This outcome was to be assessed for subjects who received Serostim® 4 mg in Period I.
Time frame: Week 36
| Milestone | Period I: Placebo | Period I: Serostim® 4 mg | Period II: Serostim® 4 mg to Placebo | Period II: Serostim® 4 mg to Serostim® 2 mg | Period II: Placebo to Placebo/Serostim® 4 mg |
|---|---|---|---|---|---|
| Started | 81 | 245 | 0 | 0 | 0 |
| Completed | 73 | 185 | 0 | 0 | 0 |
| Not completed | 8 | 60 | 0 | 0 | 0 |
| Withdrew: Subjects did not receive study drug | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Subjects without post-baseline assessmen | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Subjects did not complete week 12 | 5 | 43 | 0 | 0 | 0 |
| Withdrew: Did not continue to period ii | 1 | 15 | 0 | 0 | 0 |
| Milestone | Period I: Placebo | Period I: Serostim® 4 mg | Period II: Serostim® 4 mg to Placebo | Period II: Serostim® 4 mg to Serostim® 2 mg | Period II: Placebo to Placebo/Serostim® 4 mg |
|---|---|---|---|---|---|
| Started | 0 | 0 | 93 | 92 | 73 |
| Completed | 0 | 0 | 78 | 76 | 55 |
| Not completed | 0 | 0 | 15 | 16 | 18 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Subjects did not complete week 36 | 0 | 0 | 15 | 15 | 17 |
Absolute area of VAT was measured by cross-sectional computed tomography (CT) scan at the level of the L4-5 inter-vertebral disk. CT scanning was to be used to assess the cross sectional area of abdominal fat and its distribution between the visceral and subcutaneous compartments, as measured at L4-L5.
| Square Centimeter (cm^2) | Period I: Placebo | Period I: Serostim® 4 mg |
|---|---|---|
| Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12 | 0.5 ± 34.5 | -32.6 ± 37.9 |
Changes in trunk fat was measured as changes in mass (kg) on Dual-Energy X-Ray Absorptiometry (DXA) Scan.
| Kilogram (Kg) | Period I: Placebo | Period I: Serostim® 4 mg |
|---|---|---|
| Treatment Period I: Change From Baseline in Trunk Fat at Week 12 | 0.2 ± 1.3 | -2.2 ± 1.7 |
Body image distress was assessed on a scale ranging from 0 to 100, where 0 = Extremely Upsetting and 100 = Extremely Encouraging.
| units on a scale | Period I: Placebo | Period I: Serostim® 4 mg |
|---|---|---|
| Change From Baseline in Patient Reported Outcome of Body Image Distress at Week 12 | 0.23 ± 1.42 | 0.10 ± 1.73 |
Lipid profile data was analyzed for Non-HDL Cholesterol.
| milligram/deciliter (mg/dL) | Period I: Placebo | Period I: Serostim® 4 mg |
|---|---|---|
| Treatment Period I: Change From Baseline in Non- High-density Lipoprotein (Non-HDL) Cholesterol at Week 12 | -2.8 ± 28.1 | -13.0 ± 37.1 |
Failure rate based on VAT was assessed by CT scan at L4-L5. The failure rate was defined as the percentage of subjects who regained \>50% of their VAT lost in Treatment Period I. This outcome was to be assessed for subjects who received Serostim® 4 mg in Period I.
| percentage of subjects | Period II: Serostim® 4 mg to Placebo | Period II: Serostim® 4 mg to Serostim® 2 mg |
|---|---|---|
| Treatment Period II: Failure Rate at Week 36 Based on Visceral Adipose Tissue (VAT) For Subjects Who Received Serostim® 4 mg in Period I | 53.7 | 40.3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period I: Placebo (Week 1 to 12) | — | 2/81 (2.5%) | 70/81 (86.4%) |
| Period I: Serostim® 4 mg (Week 1 to 12) | — | 3/244 (1.2%) | 244/244 (100%) |
| Period II: Serostim® 4 mg to Placebo (Week 12 to 36) | — | 3/93 (3.2%) | 46/93 (49.5%) |
| Period II: Serostim® 4 mg to Serostim® 2 mg (Week 12 to 36) | — | 2/92 (2.2%) | 48/92 (52.2%) |
| Period II: Placebo to Placebo (Week 12 to Week 24) | — | 2/73 (2.7%) | 14/73 (19.2%) |
| Period II: Placebo to Serostim® 4 mg (Week 24 to 36) | — | 1/73 (1.4%) | 73/73 (100%) |
| Event | Period I: Placebo (Week 1 to 12) | Period I: Serostim® 4 mg (Week 1 to 12) | Period II: Serostim® 4 mg to Placebo (Week 12 to 36) | Period II: Serostim® 4 mg to Serostim® 2 mg (Week 12 to 36) | Period II: Placebo to Placebo (Week 12 to Week 24) | Period II: Placebo to Serostim® 4 mg (Week 24 to 36) |
|---|---|---|---|---|---|---|
| Groin abscessInfections and infestations | 0/81 | 0/244 | 0/93 | 0/92 | 1/73 | 0/73 |
| PneumoniaInfections and infestations | 0/81 | 0/244 | 0/93 | 0/92 | 1/73 | 0/73 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/81 | 0/244 | 0/93 | 0/92 | 0/73 | 1/73 |
| DepressionPsychiatric disorders | 1/81 | 0/244 | 0/93 | 0/92 | 0/73 | 0/73 |
| Abdominal painGastrointestinal disorders | 1/81 | 0/244 | 0/93 | 0/92 | 0/73 | 0/73 |
| PneumoniaInfections and infestations | 0/81 | 0/244 | 0/93 | 1/92 | 0/73 | 0/73 |
| DiarrhoeaInfections and infestations | 0/81 | 0/244 | 0/93 | 1/92 | 0/73 | 0/73 |
| Pancreatic insufficiencyInfections and infestations | 0/81 | 0/244 | 0/93 | 1/92 | 0/73 | 0/73 |
| NephrolithiasisRenal and urinary disorders | 0/81 | 0/244 | 0/93 | 1/92 | 0/73 | 0/73 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/81 | 0/244 | 1/93 | 0/92 | 0/73 | 0/73 |
| Event | Period I: Placebo (Week 1 to 12) | Period I: Serostim® 4 mg (Week 1 to 12) | Period II: Serostim® 4 mg to Placebo (Week 12 to 36) | Period II: Serostim® 4 mg to Serostim® 2 mg (Week 12 to 36) | Period II: Placebo to Placebo (Week 12 to Week 24) | Period II: Placebo to Serostim® 4 mg (Week 24 to 36) |
|---|---|---|---|---|---|---|
| Oedema peripheralGeneral disorders | 4/81 | 113/244 | 4/93 | 6/92 | 0/73 | 34/73 |
| ArthralgiaGeneral disorders | 14/81 | 95/244 | 5/93 | 8/92 | 2/73 | 30/73 |
| Pain in extremityGeneral disorders | 3/81 | 46/244 | 5/93 | 2/92 | 2/73 | 19/73 |
| MyalgiaGeneral disorders | 3/81 | 34/244 | 0/93 | 0/92 | 0/73 | 14/73 |
| Upper respiratory tract infectionGeneral disorders | 6/81 | 13/244 | 15/93 | 7/92 | 0/73 | 0/73 |
| HeadacheGeneral disorders | 3/81 | 39/244 | 4/93 | 5/92 | 0/73 | 8/73 |
| Blood glucose increasedGeneral disorders | 2/81 | 33/244 | 3/93 | 6/92 | 2/73 | 11/73 |
| HypoaesthesiaGeneral disorders | 0/81 | 34/244 | 1/93 | 5/92 | 0/73 | 8/73 |
| HyperglycaemiaGeneral disorders | 1/81 | 17/244 | 0/93 | 0/92 | 2/73 | 10/73 |
| Musculoskeletal stiffnessGeneral disorders | 1/81 | 18/244 | 0/93 | 0/92 | 1/73 | 9/73 |
The modified ITT Population (ITT) for Period I was defined as all subjects who had a baseline and at least one post-baseline efficacy measurement.
| Age, Continuous(Years) | Period I: Placebo | Period I: Serostim® 4 mg | Total |
|---|---|---|---|
| Mean | 45.5 ± 7.5 | 44.5 ± 7.0 | 44.8 ± 7.1 |
| Sex: Female, Male(Participants) | Period I: Placebo | Period I: Serostim® 4 mg | Total |
|---|---|---|---|
| Female | 11 | 36 | 47 |
| Male | 68 | 207 | 275 |
Ran from May 2004 to primary completion in Sep 2005, 16 months.
Results were first posted in Jul 2018, 12 years 9 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 16 months is below that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone